| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | IL5R; CD125; CDw125; HSIL5R3 |
| WB Predicted band size | 48 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human IL5RA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL5RA抗体的3篇参考文献，格式为文献名称、作者及摘要概括：
1. **"Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial"**
*Authors: Pavord ID, et al.*
**摘要**：该临床试验评估抗IL-5Rα单抗美泊利单抗(mepolizumab)治疗重度嗜酸性粒细胞性哮喘的效果，显示其显著降低哮喘急性发作频率并改善患者生活质量。
2. **"Targeting IL-5 Signaling in Eosinophilic Diseases: From Biology to Therapeutic Application"**
*Authors: Kouro T, Takatsu K.*
**摘要**：综述IL-5/IL-5Rα信号通路在嗜酸性粒细胞相关疾病中的作用，探讨靶向IL5RA的抗体(如benralizumab)通过阻断信号通路减少嗜酸性粒细胞炎症的机制及临床潜力。
3. **"Structural Basis of IL-5 Receptor Recognition by Therapeutic Antibodies"**
*Authors: Lee JH, et al.*
**摘要**：通过X射线晶体学解析IL-5Rα与单抗的结合结构，揭示抗体如何特异性阻断IL-5与受体结合，为优化靶向IL5RA的抗体药物提供结构学依据。
如需具体文献链接或更多细节，建议通过PubMed或Sci-Hub检索标题或作者名获取全文。
Interleukin-5 receptor alpha (IL5RA), a subunit of the IL-5 receptor complex, plays a critical role in the signaling pathway of interleukin-5 (IL-5), a cytokine essential for the differentiation, survival, and activation of eosinophils. Expressed predominantly on eosinophils and basophils, IL5RA pairs with the common beta chain (βc) to form a functional receptor. Dysregulation of the IL-5/IL5RA axis is implicated in eosinophil-driven inflammatory diseases, such as severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and hypereosinophilic syndromes (HES).
IL5RA-targeted antibodies, a class of biologic therapies, are designed to disrupt this pathway by blocking IL-5 binding or depleting eosinophils via antibody-dependent cellular cytotoxicity (ADCC). Benralizumab, a humanized monoclonal antibody against IL5RA, exemplifies this approach by directly targeting the alpha subunit, leading to rapid eosinophil depletion. Compared to antibodies targeting IL-5 itself (e.g., mepolizumab), IL5RA antibodies may offer enhanced efficacy due to their dual mechanism of action.
Clinical trials have demonstrated that IL5RA antibodies reduce exacerbations, improve lung function, and decrease oral corticosteroid dependence in severe eosinophilic asthma. They also show promise in treating other eosinophilic disorders. By selectively modulating eosinophil activity, these therapies minimize systemic immunosuppression risks, offering a targeted strategy for managing chronic eosinophilic inflammation. Ongoing research explores broader applications, including eosinophilic gastrointestinal diseases and atopic dermatitis.
×
